Transposon Therapeutics, Inc. is developing TPN-101 (also known as Censavudine) and other LINE-1 reverse transcriptase inhibitors for the treatment of rare neurodegenerative diseases such as progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Aicardi-Goutières Syndrome (AGS).
Location: United States, Connecticut, Westport
Employees: 1-10
Investors 2
| Date | Name | Website |
| 26.10.2023 | Lumira Ven... | lumiravent... |
| 26.09.2022 | Canaan Par... | canaan.com |
Mentions in press and media 2
| Date | Title | Description | Source |
| 13.02.2024 | Transposon Announces Final Results from a Phase 2 Study of i... | SAN DIEGO, Feb. 12, 2024 /PRNewswire/ -- Transposon Therapeutics, a biotechnology company developing... | svhealthin... |
| 14.11.2023 | Transposon Announces Interim Results from a Phase 2 Study of... | 24-Week data show TPN-101 is the first treatment for PSP to reduce NfL levels, a key biomarker of ne... | svhealthin... |